Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Sarkis Clinical Trials
mi
from
Gainesville, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Miami Research
mi
from
South Miami, FL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Miami Research
mi
from
South Miami, FL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Capstone Clinical Research
mi
from
Libertyville, IL
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Psychiatric Associates
mi
from
Overland Park, KA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
University Kentucky Psychiatry
mi
from
Lexington, KY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
University Kentucky Psychiatry
mi
from
Lexington, KY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital
mi
from
Boston, MA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Behavioral Medicine Center
mi
from
Troy, MI
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Behavioral Medicine Center
mi
from
Troy, MI
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
St Charles Psychiatric Associates
mi
from
St. Charles, MO
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
St Charles Psychiatric Associates
mi
from
St. Charles, MO
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Bioscience Research, Llc
mi
from
Mount Kisco, NY
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bioscience Research, Llc
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Duke University
mi
from
Durham, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Sequoia Behavioral Healthcare
mi
from
Media, PA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Sequoia Behavioral Healthcare
mi
from
Media, PA
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
FutureResearch Trials
mi
from
Austin, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials
mi
from
Austin, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
FutureResearch Trials Dallas, LP
mi
from
Dallas, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
FutureResearch Trials Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  4/27/2014
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
A 6 Week Randomized Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Adults With Attention Deficit/Hyperactivity )
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 4/27/2014
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
Click here to add this to my saved trials
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Status: Enrolling
Updated:  5/5/2014
Ryder Trauma Center
mi
from
Miami, FL
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
Status: Enrolling
Updated: 5/5/2014
Ryder Trauma Center
mi
from
Miami, FL
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated:  5/7/2014
UPENN Map Center for Mental Health Policy and Services Research
mi
from
Philadelphia, PA
Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools
Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.
Status: Enrolling
Updated: 5/7/2014
UPENN Map Center for Mental Health Policy and Services Research
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Music Therapy on Cognitive Recovery
I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery
Status: Enrolling
Updated:  5/13/2014
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Effect of Music Therapy on Cognitive Recovery
I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery
Status: Enrolling
Updated: 5/13/2014
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
University of California at San Diego
mi
from
San Diego, CA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
University of Maryland Medical Center, Shock Trauma Center
mi
from
Baltimore, MD
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
University of Maryland Medical Center, Shock Trauma Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
UPMC Presbyterian Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated:  5/14/2014
VCU Medical Center
mi
from
Richmond, VA
Glyburide (RP-1127) for Traumatic Brain Injury (TBI)
A Randomized Clinical Trial of Glyburide (RP-1127) for TBI
Status: Enrolling
Updated: 5/14/2014
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy
Status: Enrolling
Updated:  5/22/2014
Cedars-Sinai Heart Institute
mi
from
Los Angeles, CA
Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy
Status: Enrolling
Updated: 5/22/2014
Cedars-Sinai Heart Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated:  5/27/2014
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Status: Enrolling
Updated: 5/27/2014
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Center For United Research, Inc.
mi
from
Lakewood, CA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Center For United Research, Inc.
mi
from
Lakewood, CA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Clinical Research Consulting, LLC
mi
from
Milford, CT
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Clinical Research Consulting, LLC
mi
from
Milford, CT
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Metabolic Research Institute, Inc.
mi
from
West Palm Beach, FL
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Metabolic Research Institute, Inc.
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Novex Clinical Research, LLC
mi
from
New Bedford, MA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Novex Clinical Research, LLC
mi
from
New Bedford, MA
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Coastal Carolina Research Center
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
North Texas Endocrine Center
mi
from
Dallas, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
North Texas Endocrine Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
KRK Research
mi
from
Dallas, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
KRK Research
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Houston Foot and Ankle Care
mi
from
Houston, TX
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Houston Foot and Ankle Care
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated:  5/27/2014
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Safety Study of DA-9801 to Treat Diabetic Neuropathy
A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Status: Enrolling
Updated: 5/27/2014
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Click here to add this to my saved trials
Theta-burst Transcranial Magnetic Stimulation
Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity
Status: Enrolling
Updated:  5/28/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Theta-burst Transcranial Magnetic Stimulation
Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity
Status: Enrolling
Updated: 5/28/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Status: Enrolling
Updated:  5/29/2014
St Louis Children's Hospital
mi
from
St Louis, MO
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)
Status: Enrolling
Updated: 5/29/2014
St Louis Children's Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Status: Enrolling
Updated:  5/29/2014
UWashington
mi
from
Seattle, WA
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial
Status: Enrolling
Updated: 5/29/2014
UWashington
mi
from
Seattle, WA
Click here to add this to my saved trials
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated:  5/30/2014
Nationwide Children's Hospital Hilliard Close to Home
mi
from
Hilliard, OH
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12
Status: Enrolling
Updated: 5/30/2014
Nationwide Children's Hospital Hilliard Close to Home
mi
from
Hilliard, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Arizona Medical Center
mi
from
Tucson, AZ
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Yale University School of Medicine
mi
from
New Haven, CT
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Florida - Jacksonville
mi
from
Jacksonville, FL
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Florida - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Louisville Hospital
mi
from
Louisville, KY
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials